Feng Xiaojun, et al.
Theranostics, 2019
Abstract
Cardiovascular and metabolic diseases (CVMD) are the leading causes of death worldwide, underscoring the urgent necessity to develop new pharmacotherapies. Berberine (BBR) is an eminent component of traditional Chinese and Ayurvedic medicine for more than 2000 years. Recently, BBR has attracted much interest for its pharmacological actions in treating and/or managing CVMD. Recent discoveries of basic, translational and clinical studies have identified many novel molecular targets of BBR (such as AMPK, SIRT1, LDLR, PCSK9, and PTP1B) and provided novel evidences supporting the promising therapeutic potential of BBR to combat CVMD. Thus, this review provides a timely overview of the pharmacological properties and therapeutic application of BBR in CVMD, and underlines recent pharmacological advances which validate BBR as a promising lead drug against CVMD.
Keywords
berberine; cardiovascular diseases; metabolic diseases; targets; therapeutics.
Conflict of interest statement
Competing Interests: The authors have declared that no competing interest exists.| PMID: | 31037148 |
|---|---|
| PMCID (Free PMC Article): | PMC6485276 |
| DOI: | 10.7150/thno.30787 |
| Category: | Cardiovascular Support |
Previous article
Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease.